Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
felzartamab
- Development stage
- Phase 3
- Lead developer
- Biogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Felzartamab is a fully human monoclonal antibody that targets CD38, a protein highly expressed on mature plasma cells and malignant plasma cells. By binding to CD38 on the surface of these cells, felzartamab induces their depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), without involving complement-dependent cytotoxicity. It is being developed as an immunotherapy for immune-mediated diseases such as primary membranous nephropathy (PMN), antibody-mediated rejection in kidney transplant recipients, multiple myeloma, IgA nephropathy, and lupus nephritis. Felzartamab has received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for PMN and antibody-mediated rejection in kidney transplant patients[1][3][4][5][6][8].
- Brand names
- felzartamab
- Other names
- felzartamab
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on felzartamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on felzartamab.